Stock_Titan
Posted - 1 week ago
$SRDX Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
https://www.stocktitan.net/news/SRDX/surmodics-to-report-second-quarter-of-fiscal-2024-financial-results-boqnmju29o9m.html
Fullratio
Posted - 1 month ago
Healthcare sector stocks with high EPS growth in Q4 2023 (TTM): $RPRX $ROIV $SRDX
Stock_Titan
Posted - 1 month ago
$SRDX Surmodics to Participate in Upcoming Investor Conferences in March and April
https://www.stocktitan.net/news/SRDX/surmodics-to-participate-in-upcoming-investor-conferences-in-march-ayxv6dvt3b8v.html
DonCorleone77
Posted - 2 months ago
$SRDX 2 of 2 - Surmodics sees FY24 EPS ($1.17)- (87c), consensus ($1.16) ....The company now expects fiscal 2024 GAAP diluted loss per share to range from $(1.40) to $(1.10). The company's prior guidance called for fiscal 2024 GAAP diluted loss per share to range from $(1.55) to $(1.20). Non-GAAP diluted loss per share(4) in fiscal 2024 is now expected to range from $(1.17) to $(0.87). The company's prior guidance called for fiscal 2024 Non-GAAP diluted loss per share(4) of $(1.32) to $(0.97).
DonCorleone77
Posted - 2 months ago
$SRDX 1 of 2 - Surmodics sees FY24 EPS ($1.17)- (87c), consensus ($1.16) Surmodics now expects fiscal 2024 total revenue to range from $117M to $121M, consensus is $119.26M. representing a decrease of 12 % to 9 % compared to fiscal 2023. Excluding SurVeil DCB license fee revenue, Surmodics expects fiscal 2024 total revenue to range from $113M to $117M, representing an increase of 10% to 14% compared to fiscal 2023. The company's prior guidance called for fiscal 2024 total revenue of $116 to $121M, representing a decrease of 13 % to 9 % compared to fiscal 2023, and total revenue excluding SurVeil DCB license fee revenue( of $112 Mto $117M representing an increase of 9% to 14% compared to fiscal 2023....
DonCorleone77
Posted - 2 months ago
$SRDX Surmodics reports Q1 EPS 0c, consensus (30c) Reports Q1 revenue $30.6M, consensus $29.64M. Reports total Revenue excluding SurVeil drug-coated balloon license fee revenue of $29.6 M, an increase of 25% year-over-year GAAP net loss of $(0.8)M compared to $(7.8) million in the prior-year period Adjusted EBITDA of $3.9 million, compared to $(3.3)M in the prior-year period "We delivered total revenue growth in the first quarter that exceeded our expectations, increasing 23% year-over-year - 25% excluding SurVeil DCB license fees with impressive performance in both our Medical Device and In Vitro Diagnostics business segments," said Gary Maharaj, President and CEO of Surmodics, Inc. "Our Medical Device segment revenue benefited from record product sales, which increased 43% year-over-year fueled by sales of our vascular interventions portfolio, including strong contributions from both our SurVeil DCB and Pounce thrombectomy products...."
epsguid
Posted - 2 months ago
$SRDX reported $0.00, consensus was ($0.35) via @eWhispers #epsbeat http://eps.sh/d/srdx
Doozio
Posted - 01/31/24
$srdx 🧠 eps 2mro n it’s 🌙 in 🧠⏰
Doozio
Posted - 2 months ago
$SRDX rumor has it only da 🐑 will be shook in 2020FOUR with tightness bahhhtom of base goin into week FOUR of 2020FOUR in 🧠⏰
tickeron
Posted - 3 months ago
This is amazing! What do you think? $SRDX price moved above its 50-day Moving Average. View odds of downtrend. https://srnk.us/go/4977735
cctranscripts
Posted - 3 months ago
SurModics director just picked up 1,159 shares https://www.conferencecalltranscripts.org/summary/?id=12888832 $SRDX
DonCorleone77
Posted - 3 months ago
$SRDX 2 of 2 - Surmodics: Pounce use successfully facilitates thrombi-emboli removal below knee ....which is indicated for use in vessels 3.5 mm to 6 mm in diameter. Dr. Lucas Ferrer Cardona, a vascular surgeon with the Dell Seton Medical Center at the University of Texas Hospital in Austin, was the first physician to use the Pounce LP System. "In our first use of the device, the Pounce LP Thrombectomy System performed exceptionally well in helping our team restore blood flow to the foot for a limb-threatened patient," he said. "Using the device, we promptly removed acute and subacute thrombus from the mid-peroneal artery below the knee with no adjunctive use of thrombolytics and no embolization. Thrombi or emboli in below-the-knee vessels have traditionally been very challenging to remove. I believe this device holds great promise in filling a major gap in our treatment algorithm."
DonCorleone77
Posted - 3 months ago
$SRDX 1 of 2 - Surmodics: Pounce use successfully facilitates thrombi-emboli removal below knee Surmodics announced successful early clinical use of the company's Pounce LP or Low Profile, Thrombectomy System. The Pounce LP Thrombectomy System, which received U.S. Food and Drug Administration FDA clearance in June 2023, is currently in limited market evaluation LME , with full commercial launch planned following completion of the LME. Surmodics' Pounce Thrombectomy devices are intended for the non-surgical removal of thrombi and emboli from the peripheral arterial vasculature. The new Pounce LP Thrombectomy System is indicated for use in vessels ranging from 2 mm to 4 mm in diameter, sizes typical of vessels found below the knee. The Pounce LP System complements the original Pounce Thrombectomy System, introduced in 2021....
tickeron
Posted - 3 months ago
What do you think of this? $SRDX price exceeded its 50-day Moving Average. View odds of downtrend. https://srnk.us/go/4962288
StockAutomatePro
Posted - 3 months ago
$SRDX Chart analysis predicts a downward trend for the stock. We alerted the SELL signal at $36.8 and we were able to close this one with profit at $33.12 🔏 See more details at StockAutomate.com
StockAutomatePro
Posted - 3 months ago
$SRDX Chart is suggesting a bearish outlook for the stock. We alerted the SELL signal at $37.2 and we were able to close this one with profit at $34.2 🥳
cctranscripts
Posted - 3 months ago
SurModics director just picked up 491 shares https://www.conferencecalltranscripts.org/summary/?id=12839650 $SRDX
cctranscripts
Posted - 12/29/23
SurModics director just picked up 1,387 shares https://www.conferencecalltranscripts.org/summary/?id=12831098 $SRDX
tickeron
Posted - 12/29/23
Does this make you nervous? $SRDX MACD Histogram turned negative on December 28, 2023. View odds of downtrend. https://srnk.us/go/4954755
Doozio
Posted - 4 months ago
$SRDX rumor has it they are front running 🧠⏰ in 2020FOUR
cctranscripts
Posted - 4 months ago
SurModics: Confidential, For Use Of The Commission Only (As Permitted By Rule 14A-6(E)(2)) Defi https://www.conferencecalltranscripts.org/summary/?id=12801038 $SRDX
MarketBeat
Posted - 4 months ago
Surmodics upgraded by StockNews.com to buy. www.marketbeat.com/stocks/NASDAQ/SRDX/price-target/ $SRDX
Doozio
Posted - 4 months ago
$SRDX no 🧠👀’s then. chop chop huckleberries 🧠⏰ in 2020FOUR
tickeron
Posted - 4 months ago
Wow this is a big change! $SRDX MACD Histogram turned positive on December 8, 2023. View odds of downtrend. https://srnk.us/go/4937950
MarketBeat
Posted - 4 months ago
Surmodics downgraded by StockNews.com to hold. www.marketbeat.com/stocks/NASDAQ/SRDX/price-target/ $SRDX
tickeron
Posted - 11/30/23
How do you think the market will react to this? $SRDX MACD Histogram turned negative on November 29, 2023. View odds of downtrend. https://srnk.us/go/4929240
StockAutomatePro
Posted - 11/29/23
$SRDX The chart suggests a bearish outlook for the stock. We alerted the SELL signal at $34.6 and we were able to close this one with profit at $32.97 📊
Fullratio
Posted - 4 months ago
$SRDX debt has soared by 194% year-on-year: https://fullratio.com/stocks/nasdaq-srdx/surmodics
